Long-term safety and effectiveness of canakinumab therapy in patients with cryopyrin-associated periodic syndrome: results from the β-Confident Registry

Objective To report the long-term safety and effectiveness of canakinumab, a fully human anti-interleukin 1β monoclonal antibody, in patients with cryopyrin-associated periodic syndromes (CAPS), including familial cold autoinflammatory syndrome (FCAS), Muckle-Wells syndrome (MWS) and neonatal-onset multisystem inflammatory disease (NOMID), in a real-world setting. Methods From December 2009 to December 2015, the β-Confident Registry prospectively enrolled patients with CAPS and non-CAPS conditions who received canakinumab per routine care and were prospectively followed for up to 6 years. The registry protocol did not mandate specific visits or procedures; however, all observed adverse events (AEs) and serious adverse events (SAEs) had to be recorded. Canakinumab effectiveness was evaluated by Physician’s Global Assessment (PGA). Results Of 288 patients enrolled, 3 were excluded due to missing informed consent. Among the remaining 285 patients, 243 (85.3%) were patients with CAPS and 42 (14.7%) had atypical CAPS (6.3%) or other conditions (8.4%). The median age was 26.6 years. Based on PGA, 58 of 123 (47.2%) patients with CAPS had no disease activity at 48 months, and 65 of 123 (52.8%) experienced mild/moderate disease activity at 48 months. Among CAPS phenotypes, AE incidence rates per 100 patient-years were lowest for FCAS (73.1; 95% CI 60.3 to 87.8) compared with those with MWS (105.0; 95% CI 97.2 to 113.2) or NOMID (104.6; 95% CI 86.6 to 125.2). One hundred twenty-eight SAEs were reported in 68 patients with CAPS (incidence rate/100 patient-years, 14.0; 95% CI 11.6 to 16.6). One death (metastatic rectal adenocarcinoma in a patient with MWS) was reported. Conclusions The response to canakinumab was sustained for up to 6 years. Canakinumab demonstrated a favourable safety profile over long-term treatment in patients with CAPS. Trial registration number NCT01213641.

[1]  T. van der Poll,et al.  Safety of vaccinations in patients with cryopyrin-associated periodic syndromes: a prospective registry based study , 2017, Rheumatology.

[2]  P. Libby,et al.  Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease , 2017, The New England journal of medicine.

[3]  U. Walker,et al.  Pharmacological treatment options for cryopyrin-associated periodic syndromes , 2017, Expert review of clinical pharmacology.

[4]  S. Ozen,et al.  Diagnostic criteria for cryopyrin-associated periodic syndrome (CAPS) , 2016, Annals of the rheumatic diseases.

[5]  C. Dinarello,et al.  Treating inflammation by blocking interleukin-1 in humans. , 2013, Seminars in immunology.

[6]  J. Kuemmerle-Deschner,et al.  Canakinumab in patients with cryopyrin-associated periodic syndrome: an update for clinicians , 2013, Therapeutic advances in musculoskeletal disease.

[7]  T. van der Poll,et al.  Methodological challenges in monitoring new treatments for rare diseases: lessons from the cryopyrin-associated periodic syndrome registry , 2013, Orphanet Journal of Rare Diseases.

[8]  P. Hawkins,et al.  Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes , 2011, Annals of the rheumatic diseases.

[9]  J. Butman,et al.  Cryopyrin-Associated Periodic Syndromes , 2011, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[10]  A. Chakraborty,et al.  Canakinumab (ACZ885, a fully human IgG1 anti-IL-1β mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS) , 2011, Arthritis Research & Therapy.

[11]  W. Dixon,et al.  EULAR points to consider when establishing, analysing and reporting safety data of biologics registers in rheumatology , 2010, Annals of the rheumatic diseases.

[12]  P. Hawkins,et al.  Use of canakinumab in the cryopyrin-associated periodic syndrome. , 2009, The New England journal of medicine.

[13]  S. Holland,et al.  Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. , 2006, The New England journal of medicine.

[14]  P. Hawkins,et al.  Interleukin-1-receptor antagonist in the Muckle-Wells syndrome. , 2003, The New England journal of medicine.

[15]  H. Takada,et al.  Long-term safety and efficacy of canakinumab in cryopyrin-associated periodic syndrome: results from an open-label, phase III pivotal study in Japanese patients. , 2017, Clinical and experimental rheumatology.

[16]  H. Lachmann.  Periodic fever syndromes. , 2017, Best practice & research. Clinical rheumatology.

[17]  E. Brown,et al.  Using MedDRA , 2004, Drug safety.